Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice?: A randomised controlled trial

Diabetes Research and Clinical Practice

Volumn 63, Issue 1, 2004, Pages 57-65

  Van De Laar, Floris A ^a   Lucassen, Peter L B J ^a   Kemp, Jaco ^b   Van De Lisdonk, Eloy H ^a   Van Weel, Chris ^a   Rutten, Guy E H M ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b IQVIA   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

General practice; Sulphonylurea; The Netherlands; Glucosidase inhibitor

Indexed keywords

ACARBOSE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; TOLBUTAMIDE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERUCTATION; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 0346992137     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2003.08.006     Document Type: Article

References (16)

1. Rutten G.E.H.M., Verhoeven S., Heine R.J.et al. Dutch College of General Practitioners. Guidelines on type 2 diabetes. Huisarts Wet. 42:2000;67-84. (in Dutch).
2. A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1999, Diab. Med. 16 (1999) 716-730.
3. Goldner M.G., Knatterud G.L., Prout T.E. Effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA. 218:1971;1400-1410.
4. Sami T., Kabadi U.M., Moshiri S. The effect on metabolic control of second-generation sulphonylurea drugs in patients with NIDDM after secondary failure to first-generation agents. J. Fam. Pract. 43:1996;370-374.
5. Hasche H., Mertes G., Bruns C.et al. Effects of acarbose treatment in type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. Diab. Nutr. Metab. 12:1999;277-285.
6. Costa B., Pinol C. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulphonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group. Diabetes Res. Clin. Pract. 38:1997;33-40.
7. Hwu C.M., Ho L.T., Fuh M.M.et al. Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study. Diab. Res. Clin. Pract. 60:2003;111-118.
8. Ruige J.B., Assendelft W.J., Dekker J.M., Kostense P.J., Heine R.J., Bouter L.M. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation. 97:1998;996-1001.
9. Coniff R.F., Shapiro J.A., Seaton T.B., Bray G.A. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am. J. Med. 98:1995;443-451.
10. Salman S., Salman F., Satman I.et al. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Curr. Med. Res. Opin. 16:2001;296-306.
11. Hoffmann J., Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diab. Care. 17:1994;561-566.
12. Fölsch U.R., Spengler M., Boehme K., Sommerauer B. Efficacy of glucosidase inhibitors compared to sulphonylureas in the treatment and metabolic control of diet treated type II diabetic subjects: two long-term comparative studies. Diab. Nutr. Metab. 3:1990;63-68.
13. Spengler M., Hansel G., Boehme K. Efficacy of 6 months monotherapy with glucosidase inhibitor Acarbose versus sulphonylurea glibenclamide on metabolic control of dietary treated type II diabetics (NIDDM). Horm. Metab. Res. Suppl. 26:1992;50-51.
14. World Health Organisation, Expert Committee on Diabetes Mellitus, WHO Technical Report, No. 727, Geneva, WHO, 1985.
15. Jones B., Jarvis P., Lewis J.A., Ebbutt A.F. Trials to assess equivalence: the importance of rigorous methods [see comments] [published erratum appears in BMJ 313 (7056) (1996) 550]. BMJ. 313:1996;36-39.
16. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 287:2002;360-372.